|Post IPO Valuation|
|Seed, 7/2012 ||$207k|
|Grant, 12/2013 ||$800k|
BrainStorm Cell Therapeutics (OTC.QB: BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
NurOwn™ , our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases.
We are currently conducting a Phase IIa ALS clinical trial with NurOwn at the Hadassah University Medical Center in Jerusalem. In this safety and preliminary efficacy trial, 12 patients will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts with increasing doses. The study participants will be followed for three to six months after transplantation.
The company also plans to begin a Phase II clinical trial in the USA in 2013, pending FDA approval.
In February 2011, NurOwn was granted Orphan Drug designation by the FDA.
Over 20 publications in leading scientific journals demonstrating NurOwn’s mechanism of action, pharmacology and in vivo efficacy have been published by the scientific team.